Metabolic syndrome (the cluster of high blood pressure, elevated fasting glucose, excess abdominal fat, and abnormal cholesterol levels) affects roughly one in three adults in Western populations and substantially raises the risk of type 2 diabetes and cardiovascular disease. Researchers have increasingly turned attention to the gut microbiome as a potential contributor to these interrelated conditions, and one bacterium in particular has attracted significant scientific interest: Akkermansia muciniphila.
Akkermansia muciniphila is a gram-negative bacterium that resides in the mucus layer of the intestinal wall and normally comprises more than 1 percent of a healthy adult gut microbiome. Lower levels of this organism have been reported in some studies of people with obesity, type 2 diabetes, and features of metabolic syndrome, although a systematic review found the differences inconsistent across studies [3][4]. This article explains what the current science says about that relationship, and where the evidence still has meaningful gaps.
Key Takeaways
- Akkermansia muciniphila has been found at lower levels in some studies of people with prediabetes or type 2 diabetes, but findings were inconsistent across studies [3][4]though whether this reflects cause, effect, or both remains an active research question.
- Proposed mechanisms include strengthening gut barrier integrity to reduce inflammatory endotoxin exposure, stimulating GLP-1 secretion, and modulating immune signaling via the Amuc_1100 outer-membrane protein.
- Human clinical trial evidence remains limited; most mechanistic data comes from animal models and small, short-duration human studies that call for larger confirmatory trials.
- Diet is a possible approach, but the evidence is thin: a systematic review found few diet trials measured Akkermansia, and polyphenols are linked to higher abundance mainly in mice, with no proof of health benefit through Akkermansia [5][6][7][8][9].
- Akkermansia supplements are not FDA-approved treatments; immunocompromised individuals and those on immunosuppressive therapy should consult a physician before use.
Understanding Metabolic Syndrome and Why the Gut Is Relevant
Metabolic syndrome is not a single disease but a convergence of risk factors that together raise the likelihood of serious cardiometabolic outcomes. Clinically, it is defined by at least three of the following: abdominal obesity, elevated triglycerides, low HDL cholesterol, elevated fasting blood glucose or diagnosed type 2 diabetes, and hypertension. When these markers cluster together, cardiovascular risk and the likelihood of progressing to frank diabetes rises substantially.
At the mechanistic level, insulin resistance is widely regarded as a central driver of metabolic syndrome. When muscle, liver, and fat cells respond poorly to insulin, the pancreas compensates by secreting more of it, until, eventually, beta-cell capacity is exhausted and blood glucose rises uncontrolled. Chronic low-grade inflammation, oxidative stress, and disrupted lipid metabolism all feed into this cycle [1]. Emerging research asks whether dysbiosis, an imbalance in the gut microbial community, contributes to that same cycle by amplifying systemic inflammation and impairing metabolic signaling.
What Makes Akkermansia muciniphila Distinctive
Among thousands of bacterial species in the human gut, Akkermansia muciniphila occupies an unusual ecological niche: it lives in and feeds on the mucin layer that coats the intestinal wall. Rather than being harmful, this mucin degradation is proposed to stimulate the intestinal lining to renew and thicken its protective barrier. This is one reason why adequate Akkermansia levels are associated with stronger gut barrier function in preclinical models.
Akkermansia was detected in more people with type 2 diabetes than in controls, but at a lower load
Having Akkermansia detected and having a lot of it are different things, and this study shows both.
Case-control study in Iran: 50 adults with type 2 diabetes and 50 healthy controls. An association only; it cannot show cause. Source: Saiedi et al., Iranian journal of microbiology 2025
Data table
| Item | Value |
|---|---|
| Type 2 diabetes | 90% with Akkermansia detected |
| Healthy controls | 74% with Akkermansia detected |
Embed this chart
Free to reuse on your site. Copy the code below; please keep the credit link.
Research note: In a case-control study, relative gut A. muciniphila was lower in diabetes (0.0039) than in controls (0.0512, P = 0.03) [4].
Akkermansia also produces a distinctive outer-membrane protein called Amuc_1100, which appears to interact with Toll-like receptor 2 on intestinal epithelial cells in animal studies. This interaction has been proposed to modulate local immune tone and dampen the inflammatory signaling that underlies systemic low-grade inflammation: a hallmark of metabolic syndrome. These mechanisms have been characterized primarily in rodent studies, and extrapolating them directly to humans requires appropriate caution.
Proposed Mechanisms Linking Akkermansia to Metabolic Outcomes
Three overlapping pathways have been proposed to connect Akkermansia muciniphila to metabolic health. The first is gut barrier reinforcement: a leaky gut allows bacterial fragments such as lipopolysaccharide (LPS) to enter systemic circulation, provoking a low-grade inflammatory state that worsens insulin sensitivity. Akkermansia is thought to counteract this by promoting expression of tight-junction proteins and maintaining mucus-layer integrity.
The second pathway involves hormone signaling. Fermentation activity and mucosal interactions associated with Akkermansia may stimulate enteroendocrine L-cells to release glucagon-like peptide-1 (GLP-1), a hormone that enhances insulin secretion, slows gastric emptying, and reduces appetite. GLP-1 receptor agonists are among the most actively studied pharmacological targets in metabolic medicine today, which makes the possibility that gut bacteria could modulate GLP-1 tone particularly compelling, though the magnitude of any such effect from Akkermansia in humans has not been firmly established.
The third proposed pathway involves adipose and lipid metabolism. In mouse models of diet-induced obesity, Akkermansia supplementation has been associated with reduced fat mass, lower circulating endotoxin levels, and improved hepatic lipid profiles. These findings have not been consistently replicated in human trials at scale, and the underlying mechanisms in humans remain under investigation.
Human Evidence: Promising but Preliminary
A small number of early-phase human trials have tested Akkermansia supplementation, in both live and pasteurized forms, in overweight adults with features of metabolic syndrome. Results have been mixed. A 2019 pilot in 40 overweight or obese insulin-resistant adults found that pasteurized, but not live, Akkermansia improved insulin sensitivity versus placebo and lowered plasma total cholesterol. A 142-adult trial in adults with metabolic syndrome, using 30 billion pasteurized cells daily, did not meet its primary insulin sensitivity endpoint, and adverse events were balanced with placebo. The pilot was small and short, and the larger trial lists employees and a co-founder of the maker among its authors, so larger independent trials are needed before clinical conclusions can be drawn [10][11][12][13].
The broader field of nutritional and microbiome-targeted interventions for metabolic syndrome is actively evolving. Well-designed trials are now examining how various supplement strategies affect anthropometric measures, body composition, fasting glucose, lipid panels, blood pressure, and appetite in overweight and obese adults [2]. Rigorous randomized controlled designs that assess multiple metabolic syndrome components simultaneously will be essential for determining whether targeting the gut microbiome offers clinically meaningful benefits.
In the 142-adult metabolic syndrome trial, the gain seen in people with low baseline Akkermansia was a post hoc, exploratory subgroup result, significant at 3 months but not at 4 months [13][10].
Metabolic syndrome involves conditions where impaired beta-cell function and insulin resistance develop through complex, overlapping, and self-reinforcing pathways [1]. Any gut-targeted intervention needs to be evaluated against this multifactorial reality, not assessed in isolation from the broader metabolic context.
What Depletes Akkermansia, and What May Support It
Several common lifestyle and dietary patterns have been associated with lower Akkermansia abundance in observational research. Lower Akkermansia has been reported in some studies of people with diabetes or obesity and in Chinese centenarians compared with younger elderly people, but results are not consistent: in an inpatient study the antibiotic vancomycin raised A. muciniphila, and a review states that evidence linking exercise to Akkermansia comes mostly from animal or small human studies, with causality unclear [3][14][15][16].
On the other side, few diet trials have measured Akkermansia: a systematic review found that of 29 included trials covering 1444 participants, only five examined A. muciniphila alone. In mice, cranberry extract and green tea extract raised Akkermansia, and a review states that polyphenols may increase it. In humans the picture is mixed: a polyphenol-rich fermented black soybean product lowered LDL while Akkermansia abundance decreased in older adults, and inulin did not raise it in a pilot in adults with type 1 diabetes [5][6][7][8][9][17]. Metformin, the widely prescribed first-line diabetes medication, has also been found to increase Akkermansia abundance, though whether this relationship contributes to metformin’s metabolic effects or is a parallel association remains debated in the literature.
Practical Considerations: Supplements, Diet, and Realistic Expectations
Live and pasteurized Akkermansia muciniphila supplements are commercially available in some markets as capsules or powders. These products are not FDA-approved to treat, cure, or prevent metabolic syndrome, diabetes, or any other condition. The human evidence base remains early-stage, with most mechanistic data derived from animal models and a limited number of small human trials.
For otherwise healthy adults exploring Akkermansia supplements as part of a broader lifestyle approach to metabolic health, the small trials reported no serious safety signal, although EFSA judged the 2019 pilot of limited value for safety because of few subjects, a low dose and a short duration [13][11]. However, individuals who are immunocompromised, on immunosuppressive medications, or managing active inflammatory bowel disease should consult a physician before using any live microbial preparation, as the risk-benefit calculation differs meaningfully in these groups. Increasing dietary fiber and polyphenol intake is a common first step, but no verified trial here shows that it raises Akkermansia and improves metabolic health through it [5].
đ Where to Buy Akkermansia muciniphila
- Pendulum Akkermansia
delayed-release capsules, 100M AFU: Live A. muciniphila strain (WB-STR-0001); single-strain with chicory inulin, third-party tested. - Codeage Akkermansia Muciniphila
capsules, 100M AFU, 90 ct: Lower-cost Akkermansia plus chicory inulin synbiotic; 3-month supply, gluten-free. - Double Wood Akkermansia Probiotic + Postbiotic
capsules, per label: Budget Akkermansia option marketed around GLP-1 and postbiotic support.
As an Amazon Associate we earn from qualifying purchases. Akkermansia is a live, oxygen-sensitive strain: choose a delayed-release, third-party-tested product with a stated live AFU count.
A Note on the Evidence
The evidence linking Akkermansia muciniphila supplementation to meaningful improvements in metabolic syndrome in humans is still preliminary: most mechanistic data comes from animal models, and the completed human trials have been small and short in duration; larger confirmatory studies are needed before clinical recommendations can be made. Akkermansia supplements are not FDA-approved to treat or prevent any disease, and individuals who are immunocompromised, on immunosuppressive medications, or managing active inflammatory bowel disease should consult a qualified physician before use. This article is informational only and does not constitute medical advice.
Frequently Asked Questions
What is the proposed connection between Akkermansia and metabolic syndrome?
Lower gut levels of Akkermansia muciniphila have been reported in some studies of people with prediabetes or type 2 diabetes, but a systematic review found the differences inconsistent across studies. Proposed mechanisms, tested mainly in cells and mice, include gut barrier reinforcement and GLP-1 stimulation; a narrative review says more human research is needed to prove clinical benefit [3][18][19][20][21]..
Has Akkermansia been tested in human clinical trials for metabolic outcomes?
Yes, but the evidence base is still limited. A 2019 pilot in 40 overweight or obese insulin-resistant adults found improved insulin sensitivity and lower total cholesterol with pasteurized but not live Akkermansia, while a 142-adult trial in adults with metabolic syndrome missed its primary insulin sensitivity endpoint. Larger, well-controlled randomized trials that assess multiple metabolic syndrome components together [2] will be necessary [10][12][11][13] before firm clinical conclusions can be drawn.
Can I raise my Akkermansia levels through diet alone?
Diet is a reasonable thing to try, but the evidence is limited: a systematic review found few diet trials measured Akkermansia, polyphenols raised it mainly in mice, and inulin did not raise it in a pilot in adults with type 1 diabetes. Whether higher abundance from diet improves metabolic health has not been shown [5][6][7][8][17].
Is it safe to take an Akkermansia supplement?
A 2019 pilot in 40 overweight or obese insulin-resistant adults reported live and pasteurized Akkermansia well tolerated, and adverse events were balanced with placebo in a 142-adult metabolic syndrome trial. EFSA judged the pilot of limited value for safety, and said safety in pregnant and lactating women has not been established. Akkermansia supplements are not FDA-approved treatments, and individuals who are immunocompromised, on immunosuppressive therapy, or managing active inflammatory bowel disease should consult a qualified physician before using any live microbial preparation [12][13][11][22].
How does Akkermansia relate to GLP-1 secretion?
GLP-1 is an intestinal hormone that amplifies insulin release in response to food, reduces appetite, and slows gastric emptying: the same pathway targeted by a class of widely used diabetes and weight-loss medications. Akkermansia has been proposed, primarily in animal studies, to stimulate GLP-1 secretion through mucosal interactions and fermentation activity. Whether this translates to meaningfully elevated GLP-1 levels in humans at practical supplementation doses has not yet been established in large human trials.
Does Akkermansia abundance decline with metabolic disease?
Some studies find Akkermansia abundance lower in people with prediabetes or type 2 diabetes, but a systematic review found the differences inconsistent across studies. Evidence in older adults and with antibiotics is mixed: Chinese centenarians had lower relative abundance than younger elderly people, while the antibiotic vancomycin raised A. muciniphila in an inpatient study. Establishing clear cause-and-effect relationships in human populations is methodologically challenging given the many interacting dietary, lifestyle, and genetic variables involved [3][14][15].
References
- Long J et al. Post-transplant diabetes mellitus after kidney transplantation: pathogenesis, risk factors, and management strategies. Frontiers in endocrinology (2026). PMID 42130741
- Asghari P et al. The effects of a newly developed beverage powder supplement on anthropometric measures, body composition, metabolic syndrome components, and appetite in obese or overweight adults: a protocol for a randomized clinical trial study. Trials (2025). PMID 41163054
- Letchumanan G et al. Gut Microbiota Composition in Prediabetes and Newly Diagnosed Type 2 Diabetes: A Systematic Review of Observational Studies. Frontiers in cellular and infection microbiology (2022). PMID 36046745
- Saiedi E et al. Comparative analysis of gut microbiota composition in the fecal samples from type 2 diabetes mellitus patients and healthy individuals: a case control study. Iranian journal of microbiology (2025). PMID 41510046
- Sanne Verhoog et al. Dietary Factors and Modulation of Bacteria Strains of Akkermansia muciniphila and Faecalibacterium prausnitzii: A Systematic Review. Nutrients (2019). PMID 31336737
- Fernando F. AnhĂȘ et al. A polyphenol-rich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased Akkermansia spp. population in the gut microbiota of mice. Gut (2014). PMID 25080446
- Gurley BJ et al. Decaffeinated Green Tea Extract Does Not Elicit Hepatotoxic Effects and Modulates the Gut Microbiome in Lean B6C3Fâ Mice. Nutrients (2019). PMID 30987244
- Yuji Naito et al. A next-generation beneficial microbe: Akkermansia muciniphila. Journal of Clinical Biochemistry and Nutrition (2018). PMID 30087541
- Chang SS et al. Plant-based polyphenol rich protein supplementation attenuated skeletal muscle loss and lowered the LDL level via gut microbiota remodeling in Taiwan's community-dwelling elderly. Food & function (2023). PMID 37795525
- Liu Y et al. Pasteurized Akkermansia muciniphila as a candidate multi-effector pharmacological system in the gut-liver axis: evidence, unresolved causality, and translational priorities. Frontiers in pharmacology (2026). PMID 42846334
- European Food Safety Authority (NDA Panel) Safety of pasteurised Akkermansia muciniphila as a novel food pursuant to Regulation (EU) 2015/2283. European Food Safety Authority (NDA Panel) (2021). source
- Depommier C et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nature medicine (2019). PMID 31263284
- Suenaert P et al. Effect of pasteurized Akkermansia muciniphila MucT on insulin sensitivity, body composition, and GLP-1 production in subjects with metabolic syndrome: impact of low baseline gut Akkermansia levels. Gut microbes (2026). PMID 42343233
- Wang Fang et al. Gut Microbiota Community and Its Assembly Associated with Age and Diet in Chinese Centenarians. Journal of Microbiology and Biotechnology (2015). PMID 25839332
- Basolo A et al. Effects of underfeeding and oral vancomycin on gut microbiome and nutrient absorption in humans. Nature medicine (2020). PMID 32235930
- Yu M et al. Effects of anti-aging diets and exercise on age-related musculoskeletal diseases via gut microbiota modulation. Annals of medicine (2026). PMID 42773801
- Ojetti V et al. Efficacy of inulin supplementation in metabolic control and Akkermansia muciniphila levels in subjects with type 1 diabetes: a pilot study. European review for medical and pharmacological sciences (2026). PMID 41636295
- Fatemeh Ashrafian et al. Comparative effects of alive and pasteurized Akkermansia muciniphila on normal diet-fed mice. Scientific Reports (2021). PMID 34504116
- Wenxuan Di et al. Heterologous expression of P9 from Akkermansia muciniphila increases the GLP-1 secretion of intestinal L cells. World Journal of Microbiology and Biotechnology (2024). PMID 38727988
- Di W et al. Engineered Lactococcus lactis secreting a glucagon-like peptide-1-inducing protein P9 for amelioration of obesity in mice. 3 Biotech (2025). PMID 40822427
- Dulai AS et al. The Gut Microbiome's Influence on Incretins and Impact on Blood Glucose Control. Biomedicines (2024). PMID 39767626
- EFSA Panel on Nutrition et al. Safety of an extension of use of pasteurised Akkermansia muciniphila as a novel food pursuant to Regulation (EU) 2015/2283. EFSA journal. European Food Safety Authority (2025). PMID 41018002
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
